


Stanford



A. Dimitrios Colevas

Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) at the Stanford University Medical Center

Medicine - Oncology

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm 2328

MC 5826

Stanford, CA 94305

Tel (650) 724-9707

Fax (650) 498-5800

Bio

CLINICAL FOCUS

- Cancer > Head and Neck Cancer
- Oncology (Cancer)
- developmental therapeutics
- investigational new drugs
- Adverse event(toxicity) evaluation and reporting
- Thyroid Cancer
- combined chemotherapy and radiation treatment
- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor - Med Center Line, Medicine - Oncology
- Professor - Med Center Line (By courtesy), Otolaryngology - Head & Neck Surgery Divisions
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Residency: Johns Hopkins University School of Medicine (1992) MD
- Internship: Johns Hopkins University School of Medicine (1990) MD
- Medical Education: Johns Hopkins University School of Medicine (1989) MD
- Board Certification: Medical Oncology, American Board of Internal Medicine (1995)
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (1995) MA
- B. A., Columbia , Chemistry (1985)
- M.D., Johns Hopkins , Medicine (1989)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Multi- modality treatment of Head and Neck Cancer

Phase 1 clinical trials

CLINICAL TRIALS

- A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy, Recruiting
- A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors, Recruiting
- Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA, Recruiting
- Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC), Recruiting
- Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer, Recruiting
- Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recruiting
- 4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy, Not Recruiting
- A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC), Not Recruiting
- A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors, Not Recruiting
- A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors, Not Recruiting
- A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies, Not Recruiting
- A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients, Not Recruiting
- A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma, Not Recruiting
- A Study in Advanced Cancer, Not Recruiting
- A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma, Not Recruiting
- A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer, Not Recruiting
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers, Not Recruiting
- A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors, Not Recruiting
- A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck, Not Recruiting
- A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists, Not Recruiting
- A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study, Not Recruiting
- A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma, Not Recruiting
- A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer, Not Recruiting
- An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene, Not Recruiting
- An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene, Not Recruiting

- An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed, Not Recruiting
- Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma, Not Recruiting
- BIBW 2992 (Afatinib) in Head & Neck Cancer, Not Recruiting
- Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study, Not Recruiting
- Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin, Not Recruiting
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Not Recruiting
- Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas, Not Recruiting
- Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer, Not Recruiting
- Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma, Not Recruiting
- Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Not Recruiting
- Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer, Not Recruiting
- Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR, Not Recruiting
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Not Recruiting
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations, Not Recruiting
- FNA Tumor Sampling for CD137 Modulation: A Pilot Study, Not Recruiting
- Imaging and Biomarkers of Hypoxia in Solid Tumors, Not Recruiting
- Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer, Not Recruiting
- IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity, Not Recruiting
- Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy, Not Recruiting
- Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy, Not Recruiting
- Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer, Not Recruiting
- Oral Rigosertib for Squamous Cell Carcinoma, Not Recruiting
- Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody, Not Recruiting
- Phase 1 Trial of Oral Ixabepilone, Not Recruiting
- Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers, Not Recruiting
- Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC), Not Recruiting
- Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck, Not Recruiting
- Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer, Not Recruiting
- Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers, Not Recruiting
- Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer, Not Recruiting
- Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors, Not Recruiting
- Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma, Not Recruiting
- PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer, Not Recruiting
- QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors, Not Recruiting
- Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer, Not Recruiting
- Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide, Not Recruiting
- Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer, Not Recruiting
- Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer, Not Recruiting

- Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer, Not Recruiting
- Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer, Not Recruiting
- Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma, Not Recruiting
- Study for Treatment of Patients With Recurrent or Metastatic SCCN or SCCS, Not Recruiting
- Study of Cabozantinib (XL184) in Adults With Advanced Malignancies, Not Recruiting
- Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer, Not Recruiting
- Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Not Recruiting
- Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Not Recruiting
- Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629), Not Recruiting
- Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies, Not Recruiting
- Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma, Not Recruiting
- Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies, Not Recruiting
- Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib, Not Recruiting
- Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck, Not Recruiting
- Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC), Not Recruiting
- Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer, Not Recruiting
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer, Not Recruiting
- Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer, Not Recruiting
- Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141), Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.** *The Journal of clinical investigation*
Nambiar, D. K., Aguilera, T., Cao, H., Kwok, S., Kong, C., Bloomstein, J., Wang, Z., Rangan, V. S., Jiang, D., von Eyben, R., Liang, R., Agarwal, S., Colevas, et al
2019
- **Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer.** *Nature communications*
Nishio, N., van den Berg, N. S., van Keulen, S., Martin, B. A., Fakurnejad, S., Teraphongphom, N., Chirita, S. U., Oberhelman, N. J., Lu, G., Horton, C. E., Kaplan, M. J., Divi, V., Colevas, et al
2019; 10 (1): 5044
- **Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.** *JAMA otolaryngology-- head & neck surgery*
Saraswathula, A., Chen, M. M., Colevas, A. D., Divi, V.
2019

- **Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment.** *Head & neck*
Nishio, N., van Keulen, S., van den Berg, N. S., Lu, G., LaRoche, E. P., Davis, S. C., Martin, B. A., Fakurnejad, S., Zhou, Q., Birkeland, A. C., Kaplan, M. J., Divi, V., Colevas, et al
2019
- **Fluorescence molecular imaging for identification of high-grade dysplasia in patients with head and neck cancer.** *Oral oncology*
Fakurnejad, S., van Keulen, S., Nishio, N., Engelen, M., van den Berg, N. S., Lu, G., Birkeland, A., Baik, F., Colevas, A. D., Rosenthal, E. L., Martin, B. A.
2019; 97: 50–55
- **Cost comparison of treatment for oropharyngeal carcinoma** *LARYNGOSCOPE*
Tam, K., Orosco, R. K., Colevas, A., Bedi, N., Starmer, H. M., Beadle, B. M., Holsinger, F.
2019; 129 (7): 1604–9
- **Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Le, Q., Colevas, A., OSullivan, B., Lee, A. M., Lee, N., Ma, B., Siu, L. L., Waldron, J., Lim, C., Riaz, N., Lynn, J., Malik, S.
2019; 111 (7): 655–63
- **Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.** *Cancer*
Haddad, R., Concha-Benavente, F., Blumenschein, G. J., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Kasper, S., Vokes, E. E., Worden, F., Saba, N. F., Tahara, M., Jayaprakash, et al
2019
- **Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Ferris, R. L., Licitra, L., Fayette, J., Even, C., Blumenschein, G. R., Harrington, K. J., Guigay, J., Vokes, E. E., Saba, N. F., Haddad, R. I., Ramkumar, S., Russell, J., Brossart, et al
2019
- **The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer** *JOURNAL OF NUCLEAR MEDICINE*
van Keulen, S., Nishio, N., Fakurnejad, S., Birkeland, A., Martin, B. A., Lu, G., Zhou, Q., Chirita, S. U., Forouzanfar, T., Colevas, A., van den Berg, N. S., Rosenthal, E. L.
2019; 60 (6): 758–63
- **The Sentinel Margin: Intraoperative ex-vivo Specimen Mapping Using Relative Fluorescence Intensity.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
van Keulen, S., Nishio, N., Birkeland, A., Fakurnejad, S., Martin, B. A., Forouzanfar, T., Cunanan, K., Colevas, A. D., van den Berg, N. S., Rosenthal, E. L.
2019
- **Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.**
Gillison, M. L., Ferris, R. L., Harris, J., Colevas, A., Mell, L. K., Kong, C., Jordan, R. C., Moore, K., Minh Tam Truong, Kirsch, C., Clump, D., Ohr, J., He, K., et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV plus NPC).**
Siu, L. L., Bauml, J., Adkins, D., Colevas, A., Perez, C., Choe, J., Zhang, Y., Shi, W., Navarro, W. H., Haigentz, M., Rabinowits, G., Pfister, D. G.
AMER SOC CLINICAL ONCOLOGY.2019
- **Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.** *Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging*
Nishio, N., van den Berg, N. S., van Keulen, S., Martin, B. A., Fakurnejad, S., Zhou, Q., Lu, G., Chirita, S. U., Kaplan, M. J., Divi, V., Colevas, A. D., Rosenthal, E. L.
2019
- **Pembrolizumab with or without vismodegib for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study**
Chang, A., Tran, D. C., Cannon, J., Li, S., Jeng, M., Rieger, K., Sarin, K. Y., Yost, K., Satpathy, A., Reddy, S., Colevas, A.
ELSEVIER SCIENCE INC.2019: S92

- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers** *JOURNAL OF CLINICAL ONCOLOGY*
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019; 37 (12): 946+
- **Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.** *Journal of the National Cancer Institute*
Thu Le, Q., Dimitrios Colevas, A., O'Sullivan, B., Lee, A. W., Lee, N., Ma, B., Siu, L. L., Waldron, J., Lim, C., Riaz, N., Lynn, J., Malik, S.
2019
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019; JCO1802018
- **The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
van Keulen, S., Nishio, N., Fakurnejad, S., Birkeland, A., Martin, B. A., Lu, G., Zhou, Q., Chirita, S. U., Forouzanfar, T., Colevas, D., van den Berg, N. S., Rosenthal, E. L.
2019
- **Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Chang, A. S., Tran, D. C., Cannon, J. D., Li, S., Jeng, M., Patel, R., Van der Bokke, L., Pague, A., Brotherton, R., Rieger, K. E., Satpathy, A. T., Yost, K. E., Reddy, et al
2019; 80 (2): 564–66
- **Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial** *LANCET*
Gillison, M. L., Trotti, A. M., Harris, J., Eisbruch, A., Harari, P. M., Adelstein, D. J., Sturgis, E. M., Burtness, B., Ridge, J. A., Ringash, J., Galvin, J., Yao, M., Koyfman, et al
2019; 393 (10166): 40–50
- **Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Xiang, M., Colevas, A. D., Holsinger, F. C., Le, Q. X., Beadle, B. M.
2019; 17 (9): 1065–73
- **Intraoperative Tumor Assessment Using Real-Time Molecular Imaging in Head and Neck Cancer Patients.** *Journal of the American College of Surgeons*
Keulen, S. v., Nishio, N., Fakurnejad, S., van den Berg, N. S., Lu, G., Birkeland, A., Martin, B. A., Forouzanfar, T., Dimitrios Colevas, A., Rosenthal, E. L.
2019
- **Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma.** *Oral oncology*
van Keulen, S., van den Berg, N. S., Nishio, N., Birkeland, A., Zhou, Q., Lu, G., Wang, H., Middendorf, L., Forouzanfar, T., Martin, B. A., Colevas, A. D., Rosenthal, E. L.
2019; 88: 58–65
- **Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy** *ANNALS OF ONCOLOGY*
Chen, Y., Wang, Y., Lv, J., Li, Y., Chua, M. K., Le, Q., Lee, N., Colevas, A., Seiwert, T., Hayes, D. N., Riaz, N., Vermorken, J. B., O'Sullivan, et al
2019; 30 (1): 68–75
- **Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma** *ORAL ONCOLOGY*
van Keulen, S., van den Berg, N. S., Nishio, N., Birkeland, A., Zhou, Q., Lu, G., Wang, H., Middendorf, L., Forouzanfar, T., Martin, B. A., Colevas, A., Rosenthal, E. L.
2019; 88: 58–65
- **PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma** *OTOLARYNGOLOGY-HEAD AND NECK SURGERY*
Amoils, M., Kim, J., Lee, C., Sunwoo, J. B., Colevas, A., Aasi, S. Z., Hollmig, S., Ma, Y., Divi, V.

2019; 160 (1): 93–99

- **Development and validation of radiomic signatures of head and neck squamous cell carcinoma molecular features and subtypes.** *EBioMedicine*
Huang, C., Cintra, M., Brennan, K., Zhou, M., Colevas, A. D., Fischbein, N., Zhu, S., Gevaert, O.
2019
- **NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx**
Trotti, A., Harris, J., Gillison, M., Eisbruch, A., Harari, P. M., Adelstein, D. J., Sturgis, E. M., Galvin, J. M., Koyfman, S., Blakaj, D., Razaq, M. A., Colevas, A. D., Beitler, et al
ELSEVIER SCIENCE INC.2018: 1604–5
- **Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis** *CANCER*
Xiang, M., Holsinger, F., Colevas, A., Chen, M. M., Quynh-Thu Le, Beadle, B. M.
2018; 124 (23): 4486–94
- **Cost comparison of treatment for oropharyngeal carcinoma.** *The Laryngoscope*
Tam, K., Orosco, R. K., Dimitrios Colevas, A., Bedi, N., Starmer, H. M., Beadle, B. M., Christopher Holsinger, F.
2018
- **Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.** *Lancet (London, England)*
Gillison, M. L., Trotti, A. M., Harris, J., Eisbruch, A., Harari, P. M., Adelstein, D. J., Sturgis, E. M., Burtneess, B., Ridge, J. A., Ringash, J., Galvin, J., Yao, M., Koyfman, et al
2018
- **Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Chen, Y., Wang, Y., Lv, J., Li, Y., Chua, M. L., Le, Q., Lee, N., Colevas, A. D., Seiwert, T., Hayes, D. N., Riaz, N., Vermorken, J. B., O'Sullivan, et al
2018
- **Cisplatin or Carboplatin-Based Chemoradiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Population-Based Comparison**
Xiang, M., Holsinger, F. C., Colevas, A. D., Hara, W., Le, Q. T., Beadle, B. M.
ELSEVIER SCIENCE INC.2018: E371
- **Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.** *Cancer*
Xiang, M., Holsinger, F. C., Colevas, A. D., Chen, M. M., Le, Q., Beadle, B. M.
2018
- **Safety and Clinical Activity of Atezolizumab in Head and Neck Cancer: Results From a Phase I Trial.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Colevas, A. D., Bahleda, R., Braiteh, F., Balmanoukian, A., Brana, I., Chau, N. G., Sarkar, I., Molinero, L., Grossman, W., Kabbinar, F., Fasso, M., O'Hear, C., Powderly, et al
2018
- **Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age** *ORAL ONCOLOGY*
Chen, M. M., Colevas, A., Megwalu, U., Divi, V.
2018; 84: 71–75
- **CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer** *ONCOLOGIST*
Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, et al
2018; 23 (9): 1079–82
- **Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence** *CANCER RESEARCH*
Gao, R. W., Teraphongphom, N. T., van den Berg, N. S., Martin, B. A., Oberhelman, N. J., Divi, V., Kaplan, M. J., Hong, S. S., Lu, G., Ertsey, R., Tummers, W. J., Gomez, A. J., Holsinger, et al
2018; 78 (17): 5144–54

- **A case of combination PD-1 inhibitor and intralesional 5-fluorouracil for high-frequency nonmelanoma skin cancers in an immunocompromised patient**
Duy Tran, Lee, C., Colevas, A., Chang, A.
MOSBY-ELSEVIER.2018: AB6
- **Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence.** *Cancer research*
Gao, R. W., Teraphongphom, N. T., van den Berg, N. S., Martin, B. A., Oberhelman, N. J., Divi, V., Kaplan, M. J., Hong, S. S., Lu, G., Ertsey, R., Tummers, W. S., Gomez, A. J., Holsinger, et al
2018
- **Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck** *ONCOLOGIST*
Trieu, V., Pinto, H., Riess, J. W., Lira, R., Luciano, R., Coty, J., Boothroyd, D., Colevas, A.
2018; 23 (7): 764-+
- **Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141**
Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, et al
AMER ASSOC CANCER RESEARCH.2018
- **PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.** *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*
Amoils, M., Kim, J., Lee, C., Sunwoo, J. B., Colevas, A. D., Aasi, S. Z., Hollmig, S. T., Ma, Y., Divi, A. V.
2018: 194599818788057
- **Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression** *ORAL ONCOLOGY*
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, et al
2018; 81: 45-51
- **Comparative Effectiveness and Toxicity of Cetuximab or Cisplatin With Concurrent Radiation for Locoregionally Advanced Squamous Cell Carcinoma of The Head And Neck: A Population-Based Analysis**
Xiang, M., Holsinger, F., Chen, M., Colevas, A., Beadle, B.
ELSEVIER SCIENCE INC.2018: E16
- **NCCN Guidelines (R) Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Colevas, A., Yom, S. S., Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Eisele, D. W., Fenton, et al
2018; 16 (5): 479-90
- **Comparative Effectiveness of Cetuximab or Cisplatin With Concomitant Radiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Population-Based Analysis**
Xiang, M., Holsinger, F. C., Chen, M. M., Colevas, A. D., Beadle, B. M.
ELSEVIER SCIENCE INC.2018: 1322
- **Survival Benefit of Postoperative Chemotherapy for Intermediate-Risk Advanced Stage Head and Neck Cancer**
Chen, M. M., Colevas, A. D., Megwalu, U., Divi, V.
ELSEVIER SCIENCE INC.2018: 1326
- **Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504**
Gillison, M., Ferris, R. L., Zhang, Q., Colevas, A. D., Mell, L. K., Kirsch, C., Moore, K. L., Truong, M. T., Kong, C. S., Jordan, R., Clump, D. A., Ohr, J., He, et al
ELSEVIER SCIENCE INC.2018: 1307-8
- **Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups**
Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, et al
ELSEVIER SCIENCE INC.2018: 1317

- **Panitumumab-IRDye800 as an Optical Agent for Image-Guided Surgery in Patients With Squamous Cell Carcinoma**
Gao, R. W., Teraphongphom, N., van den Berg, N. S., Hong, S., Martin, B. A., Divi, V., Kaplan, M. J., Ertsey, R., Oberhelman, N. J., Lu, G., Kong, C. S., Colevas, A. D., Rosenthal, et al
ELSEVIER SCIENCE INC.2018: 1312–13
- **A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy** *JOURNAL OF THORACIC DISEASE*
Gubens, M. A., Chuang, J. C., Akerley, W., Langer, C. J., Clement-Duchene, C., San Pedro-Salcedo, M., Colevas, A., Dragnev, K., Socinski, M. A., Wakelee, H. A.
2018; 10 (1): 219–27
- **Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.** *Journal of the American Academy of Dermatology*
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S., Jeng, M., Patel, R., Van der Bokke, L., Pague, A., Brotherton, R., Rieger, K. E., Satpathy, A. T., Yost, K. E., Reddy, et al
2018
- **Nivolumab (Nivo) vs Investigator's Choice (IC) for Platinum-Refractory (PR) Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141): Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy**
Kasper, S., Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, et al
KARGER.2018: 96
- **Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers** *THERANOSTICS*
Gao, R. W., Teraphongphom, N., de Boer, E., van den Berg, N. S., Divi, V., Kaplan, M. J., Oberhelman, N. J., Hong, S. S., Capes, E., Colevas, A., Warram, J. M., Rosenthal, E. L.
2018; 8 (9): 2488–95
- **Nivolumab vs Investigator'S Choice (IC) in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use**
Ferris, R. L., Licitra, L., Fayette, J., Even, C., Blumenschein, G., Harrington, K. J., Guigay, J., Vokes, E. E., Saba, N. F., Haddad, R., Ramkumar, S., Russell, J., Brossart, et al
WILEY.2017: 143
- **Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)**
Concha-Benavente, F., Gillison, M. L., Blumenschein, G., Harrington, K. J., Fayette, J., Colevas, A., Licitra, L., Kasper, S., Even, C., Worden, F., Saba, N. F., Haddad, R., Tahara, et al
WILEY.2017: 141
- **Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy**
Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, et al
WILEY.2017: 144
- **Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes**
Haddad, R., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Kasper, S., Vokes, E. E., Worden, F., Saba, N. F., Tahara, M., Concha-Benavente, F., Monga, et al
OXFORD UNIV PRESS.2017
- **Commentary on "Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data"** *ONCOLOGIST*
Colevas, A.
2017; 22 (9): 1022–23
- **Treatment beyond progression with nivolumab (nivo) in patients with recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the phase 3 CheckMate 141 study**
Kasper, S., Haddad, R., Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Vokes, E. E., Worden, F., Saba, N. F., Tahara, M., Monga, et al
KARGER.2017: 250+

- **Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results**
Bahleda, R., Braiteh, F. S., Balmanoukian, A. S., Brana, I., Hodi, F. S., Garbo, L., Liu, B., Molinero, L., O'Hear, C., Shen, X., Colevas, A. D.
OXFORD UNIV PRESS.2017
- **Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial** *LANCET ONCOLOGY*
Harrington, K. J., Ferris, R. L., Blumenschein, G., Colevas, A., Fayette, J., Licitra, L., Kasper, S., Even, C., Vokes, E. E., Worden, F., Saba, N. F., Kiyota, N., Haddad, et al
2017; 18 (8): 1104–15
- **PD-1 inhibition for cutaneous squamous cell carcinoma: A study of six consecutive cases**
Duy Tran, Colevas, A., Chang, A.
MOSBY-ELSEVIER.2017: AB193
- **NCCN Guidelines (R) Insights Head and Neck Cancers, Version 2.2017** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Adelstein, D., Gillison, M. L., Pfister, D. G., Spencer, S., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A., Eisele, D. W., Fenton, et al
2017; 15 (6): 761–70
- **A randomized phase II study of chemoradiation (CRT) plus +/- nivolumab (Nivo) with sequential safety evaluations of Nivo plus +/- lirilumab (Liri) or ipilimumab (Ipi) concomitant with (C) RI in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593).**
Gillison, M. L., Ferris, R. L., Zhang, Q., Colevas, A., Mell, L. K., Kong, C., Jordan, R., Moore, K., Truong, M., Kirsch, C., Machtay, M., Curran, W., Le, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).**
Concha-Benavente, F., Gillison, M. L., Blumenschein, G. R., Harrington, K., Fayette, J., Colevas, A., Licitra, L., Kasper, S., Even, C., Worden, F. P., Saba, N. F., Haddad, R. I., Tahara, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.**
Sacco, A., Messer, K., Leidner, R. S., Colevas, A., Nieva, J. J., Chau, N., Nangia, C., Pinsky, B., Gold, K. A., Daniels, G. A., Cohen, E. W.
AMER SOC CLINICAL ONCOLOGY.2017
- **Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.** *JAMA dermatology*
Freites-Martinez, A., Kwong, B. Y., Rieger, K. E., Coit, D. G., Colevas, A. D., Lacouture, M. E.
2017
- **E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx-ECOG-ACRIN Cancer Research Group** *AMERICAN JOURNAL OF PSYCHOLOGY*
Marur, S., Li, S., Cmelak, A. J., Gillison, M. L., Zhao, W. J., Ferris, R. L., Westra, W. H., Gilbert, J., Bauman, J. E., Wagner, L. I., Trevarthen, D. R., Balkrishna, J., Murphy, et al
2017; 130 (1): 490-U169
- **Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.** *Head & neck*
Amoils, M., Lee, C. S., Sunwoo, J., Aasi, S. Z., Hara, W., Kim, J., Sirjani, D., Colevas, A. D., Chang, A. L., Divi, V.
2017
- **Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).**
Ferris, R. L., Concha-Benavente, F., Blumenschein, G. R., Harrington, K. J., Fayette, J., Colevas, A., Licitra, L. F., Kasper, S., Even, C., Gillison, M. L., Worden, F., Saba, N. F., Haddad, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy** *ANNALS OF ONCOLOGY*
MAKKOUK, A., Sundaram, V., Chester, C., Chang, S., Colevas, A. D., Sunwoo, J. B., Maecker, H., Desai, M., Kohrt, H. E.
2017; 28 (2): 415-420
- **E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.** *Journal of clinical oncology*

- Marur, S., Li, S., Cmelak, A. J., Gillison, M. L., Zhao, W. J., Ferris, R. L., Westra, W. H., Gilbert, J., Bauman, J. E., Wagner, L. I., Trevarthen, D. R., Balkrishna, J., Murphy, et al
2016; JCO2016683300-?
- **Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.** *Cancer*
Pan, J. J., Ng, W. T., Zong, J. F., Lee, S. W., Choi, H. C., Chan, L. L., Lin, S. J., Guo, Q. J., Sze, H. C., Chen, Y. B., Xiao, Y. P., Kan, W. K., O'Sullivan, et al
2016; 122 (21): 3307-3315
 - **Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck** *NEW ENGLAND JOURNAL OF MEDICINE*
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, et al
2016; 375 (19): 1856-1867
 - **Characterizing CD137 Upregulation on NK cells in Patients Receiving Monoclonal Antibody Therapy.** *Annals of oncology*
MAKKOUK, A., Sundaram, V., Chester, C., Chang, S., Colevas, A. D., Sunwoo, J. B., Maecker, H., Desai, M., Kohrt, H. E.
2016
 - **Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.** *JAMA dermatology*
Tran, D. C., Colevas, A. D., Chang, A. L.
2016
 - **A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.** *Investigational new drugs*
Rosen, L. S., LoRusso, P., Ma, W. W., Goldman, J. W., Weise, A., Colevas, A. D., Adjei, A., Yazji, S., Shen, A., Johnston, S., Hsieh, H., Chan, I. T., Sikic, et al
2016; 34 (5): 604-613
 - **BRAF inhibitor therapy of primary ameloblastoma** *ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY*
Tan, S., Pollack, J. R., Kaplan, M. J., Colevas, A., West, R. B.
2016; 122 (4): 518-19
 - **Design and rationale of a prospective, multi-institutional registry for patients with sinonasal malignancy.** *Laryngoscope*
Beswick, D. M., Holsinger, F. C., Kaplan, M. J., Fischbein, N. J., Hara, W., Colevas, A. D., Le, Q., Berry, G. J., Hwang, P. H.
2016; 126 (9): 1977-1980
 - **Ameloblastoma: a clinical review and trends in management** *EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY*
McClary, A. C., West, R. B., McClary, A. C., Pollack, J. R., Fischbein, N. J., Holsinger, C. F., Sunwoo, J., Colevas, A. D., Sirjani, D.
2016; 273 (7): 1649-1661
 - **BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response** *ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY*
Tan, S., Pollack, J. R., Kaplan, M. J., Colevas, A. D., West, R. B.
2016; 122 (1): E5-E7
 - **Third party assessment of resection margin status in head and neck cancer.** *Oral oncology*
Ransohoff, A., Wood, D., Solomon Henry, A., Divi, V., Colevas, A.
2016; 57: 27-31
 - **Third party assessment of resection margin status in head and neck cancer** *ORAL ONCOLOGY*
Ransohoff, A., Wood, D., Henry, A. S., Divi, V., Colevas, A.
2016; 57: 27-31
 - **Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Narayanan, S., Colevas, A. D.
2016; 17 (6)
 - **A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers**
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
AMER SOC CLINICAL ONCOLOGY.2016

- **Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.**
Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A., Licitra, L. F., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F. P., Haddad, R. I., Kiyota, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).**
Rischin, D., Boyer, M. J., Brzezniak, C. E., Colevas, A., Doebele, R., Gilbert, J., Gitlitz, B., Khan, S. A., Mehra, R., Seiwert, T. Y., Kroll, S., Pearce, T. E., Liu, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas** *CANCER*
Roberts, T. J., Colevas, A. D., Hara, W., Holsinger, F. C., Oakley-Girvan, I., Divi, V.
2016; 122 (9): 1388-1397
- **Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.** *JAMA dermatology*
Ally, M. S., Ransohoff, K., Sarin, K., Atwood, S. X., Rezaee, M., Bailey-Healy, I., Kim, J., Beachy, P. A., Chang, A. L., Oro, A., Tang, J. Y., Colevas, A. D.
2016; 152 (4): 452-456
- **Regionally Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck: Survival and High-Risk Features**
Amoils, M., Lee, C. S., Sunwoo, J., Aasi, S. Z., Hara, W., Kim, J., Sirjani, D., Colevas, A. D., Chang, A. S., Divi, V.
ELSEVIER SCIENCE INC.2016: 954
- **A Pilot Study of Electronic Quality of Life Assessments Using Tablet Devices During and After Treatment of Head and Neck Cancers**
Wang, E., Pollom, E., Bui, T., Ognibene, G., von Eyben, R., Divi, V., Sunwoo, J., Kaplan, M., Colevas, A. D., Le, Q. T., Hara, W.
ELSEVIER SCIENCE INC.2016: 969
- **Prognostic Value of Lymph Node Status Is Greater Than Lymph Node Ratio and AJCC N Staging for Head and Neck Squamous Cell Carcinomas**
Roberts, T., Colevas, A. D., Hara, W., Holsinger, F. C., Oakley-Girvan, I., Divi, V.
ELSEVIER SCIENCE INC.2016: 911-12
- **Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.** *Cancer*
Pan, J. J., Ng, W. T., Zong, J. F., Chan, L. L., O'Sullivan, B., Lin, S. J., Sze, H. C., Chen, Y. B., Choi, H. C., Guo, Q. J., Kan, W. K., Xiao, Y. P., Wei, et al
2016; 122 (4): 546-558
- **Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review** *ORAL ONCOLOGY*
Zhu, G. A., Lira, R., Colevas, A. D.
2016; 53: 36-41
- **Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review.** *Oral oncology*
Zhu, G. A., Lira, R., Colevas, A. D.
2016; 53: 36-41
- **Design and rationale of a prospective multi-institutional registry for patients with sinusoidal malignancy** *The Laryngoscope*
Beswick, D. M., Holsinger, F. C., Kaplan, M. J., Fischbein, N. J., Hara, W. Y., Colevas, A. D., Le, Q. T., Berry, G. J., Hwang, P. H.
2016
- **A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor** *JAMA DERMATOLOGY*
Chang, A. S., Kim, J., Luciano, R., Sullivan-Chang, L., Colevas, A. D.
2016; 152 (1): 106-8
- **Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma** *JAMA Dermatology*
Sarin, K. Y., Ally, M. S., Ransohoff, K. J., Atwood, S. X., Rezaee, M.
2016: 1-5
- **A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers.** *Oral oncology*

- Pollom, E. L., Wang, E., Bui, T. T., Ognibene, G., von Eyben, R., Divi, V., Sunwoo, J., Kaplan, M., Dimitri Colevas, A., Le, Q., Hara, W. Y.
2015; 51 (12): 1132-1137
- **New Diseases and New Treatments-Head and Neck Cancer Updates Preface** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Colevas, A.
2015; 29 (6): XIII-XIV
 - **Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck** *ONCOLOGIST*
Iberri, D. J., Colevas, A. D.
2015; 20 (12): 1393-1403
 - **NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Kurzrock, R., Colevas, A. D., Olszanski, A., Akerley, W., Arteaga, C. L., Carson, W. E., Clark, J. W., DiPersio, J. F., Ettinger, D. S., Morgan, R. J., Schwartzberg, L. S., Venook, A. P., Gocke, et al
2015; 13 (11): 1337-1346
 - **Outcomes of Young Patients With Oral Cavity Squamous Cell Carcinoma**
Shah, J. L., Bui, T., Kaplan, M., Colevas, A. D., Le, Q. T., Hara, W.
ELSEVIER SCIENCE INC.2015: S214
 - **Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Morgan, R. J., Synold, T. W., Longmate, J. A., Quinn, D. I., Gandara, D., Lenz, H., Ruel, C., Xi, B., Lewis, M. D., Colevas, A. D., Doroshow, J., Newman, E. M.
2015; 76 (5): 897-907
 - **Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.** *JAMA dermatology*
Pollom, E. L., Bui, T. T., Chang, A. L., Colevas, A. D., Hara, W. Y.
2015; 151 (9): 998-1001
 - **Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.** *JAMA dermatology*
Pollom, E. L., Bui, T. T., Chang, A. L., Colevas, A. D., Hara, W. Y.
2015; 151 (9): 998-1001
 - **Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.** *Head & neck*
Colevas, A. D., Lira, R. R., Colevas, E. A., Lavori, P. W., Chan, C., Shultz, D. B., Chang, K. W.
2015; 37 (8): 1102-1107
 - **Head and Neck Cancers, Version 1.2015 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtneess, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Foote, R. L., Gilbert, J., Gillison, et al
2015; 13 (7): 847-856
 - **Head and Neck Cancers, Version 1.2015.** *Journal of the National Comprehensive Cancer Network*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtneess, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Foote, R. L., Gilbert, J., Gillison, et al
2015; 13 (7): 847-856
 - **Third party assessment of resection margin status in head and neck cancer.**
Ransohoff, A., Wood, D., Henry, S., Divi, V., Colevas, A.
AMER SOC CLINICAL ONCOLOGY.2015
 - **Low pre-operative absolute monocyte count to predict overall survival benefit for oral cavity squamous cell carcinoma**
Bui, T., Shah, J., Kaplan, M., Colevas, A., Quynh-Thu Le, Hara, W.
AMER SOC CLINICAL ONCOLOGY.2015
 - **Outcomes of elderly patients treated for oral cavity squamous cell carcinoma**
Shah, J., Kaplan, M., Colevas, A., Quynh-Thu Le, Hara, W.

AMER SOC CLINICAL ONCOLOGY.2015

- **A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma** *CLINICAL CANCER RESEARCH*
Galloway, T. J., Wirth, L. J., Colevas, A. D., Gilbert, J., Bauman, J. E., Saba, N. F., Raben, D., Mehra, R., Ma, A. W., Atoyian, R., Wang, J., Burtress, B., Jimeno, et al
2015; 21 (7): 1566-1573
- **Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.** *Head & neck*
Tang, C., Chan, C., Jiang, W., Murphy, J. D., von Eyben, R., Colevas, A. D., Pinto, H., Lee-Enriquez, N., Kong, C., Le, Q.
2015; 37 (3): 386-392
- **Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients** *ONCOLOGIST*
Gruber, J. J., Colevas, A. D.
2015; 20 (2): 113-126
- **Advances in Nanotechnology and Microfluidics for Human Papillomavirus Diagnostics** *PROCEEDINGS OF THE IEEE*
Tasoglu, S., Tekin, H. C., Inci, F., Knowlton, S., Wang, S., Wang-Johanning, F., Johanning, G., Colevas, D., Demirci, U.
2015; 103 (2): 161-178
- **Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.** *The oncologist*
Iberri, D. J., Colevas, A. D.
2015
- **Phase I Trial of Bortezomib (PS-341; NSC 681239) and "Nonhybrid" (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms** *CLINICAL CANCER RESEARCH*
Holkova, B., Kmiecik, M., Perkins, E. B., Bose, P., Baz, R. C., Roodman, G. D., Stuart, R. K., Ramakrishnan, V., Wan, W., Peer, C. J., Dawson, J., Kang, L., Honeycutt, et al
2014; 20 (22): 5652-5662
- **Head and Neck Cancers, Version 2.2014** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtress, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al
2014; 12 (10): 1454-1487
- **Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtress, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al
2014; 12 (10): 1454-1487
- **CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma.** *Oncotarget*
Murillo-Sauca, O., Chung, M. K., Shin, J. H., Karamboulas, C., Kwok, S., Jung, Y. H., Oakley, R., Tysome, J. R., Farnebo, L. O., Kaplan, M. J., Sirjani, D., Divi, V., Holsinger, et al
2014; 5 (16): 6854-6866
- **E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).**
Cmelak, A., Li, S., Marur, S., Zhao, W., Westra, W. H., Chung, C. H., Gillison, M. L., Gilbert, J., Bauman, J. E., Wagner, L. I., Ferris, R. L., Trevarthen, D. R., Colevas, et al
AMER SOC CLINICAL ONCOLOGY.2014
- **Targeting CD137 enhances the efficacy of cetuximab.** *journal of clinical investigation*
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., Troutner, E., Richards, L., Rajapaska, et al
2014; 124 (6): 2668-2682
- **Targeting CD137 enhances the efficacy of cetuximab.** *journal of clinical investigation*
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., Troutner, E., Richards, L., Rajapaska, et al
2014; 124 (6): 2668-2682

- **Review of pathologic diagnosis in head and neck cancer patients: Why do it?**
Zhu, G., Lira, R. R., Colevas, A.
AMER SOC CLINICAL ONCOLOGY.2014
- **E1308: Reduced-dose INERT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).**
Cmelak, A., Li, S., Marur, S., Zhao, W., Westra, W. H., Chung, C. H., Gillison, M. L., Gilbert, J., Bauman, J. E., Wagner, L. I., Ferris, R. L., Trevarthen, D. R., Colevas, et al
AMER SOC CLINICAL ONCOLOGY.2014
- **Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
Colevas, A. D.
2014; 36 (1): 34-42
- **Phase 1b, Multicenter, Single Blinded, Placebo-Controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects With Locally Advanced Head and Neck Cancer Receiving Induction Chemotherapy** *CANCER*
Limaye, S. A., Haddad, R. I., Cilli, F., Sonis, S. T., Colevas, A. D., Brennan, M. T., Hu, K. S., Murphy, B. A.
2013; 119 (24): 4268-4276
- **Long-Term Outcomes of Surgery Followed by Radiation Therapy for Minor Salivary Gland Carcinomas** *LARYNGOSCOPE*
Zeidan, Y. H., Shultz, D. B., Murphy, J. D., Chan, C., Kaplan, M. J., Colevas, A. D., Kong, C., Chang, D. T., Le, Q.
2013; 123 (11): 2675-2680
- **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma** *BRITISH JOURNAL OF DERMATOLOGY*
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.
2013; 169 (3): 673-676
- **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.** *British journal of dermatology*
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.
2013; 169 (3): 673-676
- **Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Ang, K., Brizel, D. M., Burtness, B. A., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al
2013; 11 (8): 917-923
- **Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.** *Journal of the National Comprehensive Cancer Network*
Pfister, D. G., Ang, K., Brizel, D. M., Burtness, B. A., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al
2013; 11 (8): 917-923
- **Stereotactic radiosurgery for retreatment of gross perineural invasion in recurrent cutaneous squamous cell carcinoma of the head and neck.** *American journal of clinical oncology*
Tang, C., Fischbein, N. J., Murphy, J. D., Chu, K. P., Bavan, B., Dieterich, S., Hara, W., Kaplan, M. J., Colevas, A. D., Le, Q.
2013; 36 (3): 293-298
- **E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC)**
Marur, S., Li, S., Cmelak, A., Gillison, M. L., Ferris, R. L., Bauman, J. E., Zhao, W., Westra, W. H., Chung, C. H., Wagner, L. I., Trevarthen, D. R., Jahagirdar, B. N., Colevas, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence.** *Cancer*
Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., Colevas, A. D., Fischbein, N. J., Quon, A., Le, Q., Pinto, H. A., Fee, W. E., Sunwoo, J. B., Sirjani, et al
2013; 119 (7): 1349-1356
- **Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence** *CANCER*
Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., Colevas, A. D., Fischbein, N. J., Quon, A., Quynh-Thu Le, Q. T., Pinto, H. A., Fee, W. E., Sunwoo, J. B., Sirjani, et al

2013; 119 (7): 1349-1356

- **Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Percival, M. E., Colevas, A. D.
2013
- **Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
LoRusso, P. M., Piha-Paul, S. A., Mita, M., Colevas, A. D., Malhi, V., Colburn, D., Yin, M., Low, J. A., Graham, R. A.
2013; 71 (1): 193-202
- **Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors** *INVESTIGATIONAL NEW DRUGS*
Kunz, P. L., He, A. R., Colevas, A. D., Pishvaian, M. J., Hwang, J. J., Clemens, P. L., Messina, M., Kaleta, R., Abrahao, F., Sikic, B. I., Marshall, J. L.
2012; 30 (6): 2364-2370
- **Postoperative Radiation Therapy for Minor Salivary Gland Carcinomas of the Head and Neck: Long-term Outcomes**
Zeidan, Y., Murphy, J. D., Chan, C., An, Y., Kaplan, M., Colevas, A., Kong, C., Le, Q.
ELSEVIER SCIENCE INC.2012: S500
- **A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261** *GYNECOLOGIC ONCOLOGY*
Bible, K. C., Peethambaram, P. P., Oberg, A. L., Maples, W., Groteluschen, D. L., Boente, M., Burton, J. K., Dahl, L. C., Tibodeau, J. D., Isham, C. R., Maguire, J. L., Shridhar, V., Kukla, et al
2012; 127 (1): 55-62
- **Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Trakul, N., Chang, C. N., Harris, J., Chapman, C., Rao, A., Shen, J., Quinlan-Davidson, S., Filion, E. J., Wakelee, H. A., Colevas, A. D., Whyte, R. I., Dieterich, S., Maxim, et al
2012; 84 (1): 231-237
- **A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours** *BRITISH JOURNAL OF CANCER*
Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R., Colevas, A. D., Shepherd, F. A., Leighl, N. B., Neal, J. W., Thibault, A., Liu, L., Lisano, J., Gao, B., Lawson, et al
2012; 107 (4): 604-611
- **Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.** *International journal of radiation oncology, biology, physics*
Tang, C., Murphy, J. D., Khong, B., La, T. H., Kong, C., Fischbein, N. J., Colevas, A. D., Iagaru, A. H., Graves, E. E., Loo, B. W., Le, Q.
2012; 83 (5): 1514-1520
- **Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Tang, C., Murphy, J. D., Khong, B., La, T. H., Kong, C., Fischbein, N. J., Colevas, A. D., Iagaru, A. H., Graves, E. E., Loo, B. W., Quynh-Thu Le, Q. T.
2012; 83 (5): 1514-1520
- **A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma** *MELANOMA RESEARCH*
Kim, K. B., Prieto, V., Joseph, R. W., Diwan, A. H., Gallick, G. E., Papadopoulos, N. E., Bedikian, A. Y., Camacho, L. H., Hwu, P., Ng, C. S., Wei, W., Johnson, M. M., Wittemer, et al
2012; 22 (4): 294-301
- **Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Bose, P., Perkins, E. B., Honeycut, C., Wellons, M. D., Stefan, T., Jacobberger, J. W., Kontopodis, E., Beumer, J. H., Egorin, M. J., Imamura, C. K., Figg, W. D., Karp, J. E., Koc, et al
2012; 69 (6): 1657-1667
- **Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*

- Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W., Clarke, M. F., Carlson, R. W., Sunwoo, J., Tedder, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Hearing evaluation of head and neck cancer patients (HNCP): Comparison of adverse event (AE) criteria**
Colevas, A., Lira, R. R., Colevas, E. A., Lavori, P. W., Chang, K. W.
AMER SOC CLINICAL ONCOLOGY.2012
 - **Phase Ib, multicenter, single-blinded, placebo-controlled, sequential dose-escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer (LAHNC) receiving induction chemotherapy (ICT).** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Limaye, S. A., Sonis, S. T., Cilli, F., Colevas, A. D., Brennan, M., Hu, K., Haddad, R. I., Murphy, B. A.
AMER SOC CLINICAL ONCOLOGY.2012
 - **ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Marur, S., Lee, J., Cmelak, A., Zhao, W., Westra, W. H., Chung, C. H., Gillison, M. L., Gilbert, J., Bauman, J. E., Wagner, L. I., Ferris, R. L., Trevarthen, D. R., Colevas, et al
AMER SOC CLINICAL ONCOLOGY.2012
 - **Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure** *52nd Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO)*
Wiegner, E. A., Daly, M. E., Murphy, J. D., Abelson, J., Chapman, C. H., Chung, M., Yu, Y., Colevas, A. D., Kaplan, M. J., Fischbein, N., Quynh-Thu Le, Q. T., Chang, D. T.
ELSEVIER SCIENCE INC.2012: 243–51
 - **A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., Pedro-Salcedo, M. S., Decker, R., Latz, J. E., Wakelee, H. A.
2012; 69 (4): 1013-1020
 - **Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer** *CANCER INVESTIGATION*
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., Ganjoo, K., Colevas, A. D., San Pedro-Salcedo, M., Kuo, C. J., Wakelee, H. A.
2012; 30 (3): 231-235
 - **Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Cao, H., Banh, A., Kwok, S., Shi, X., Wu, S., Krakow, T., Khong, B., Bavan, B., Bala, R., Pinsky, B. A., Colevas, D., Pourmand, N., Koong, et al
2012; 82 (3): E351-E358
 - **Mucosal Melanoma of the Head and Neck** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Ang, K., Brizel, D. M., Burtness, B., Cmelak, A. J., Dimitrios Colevas, A., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, R. I., Haughey, B. H., Hicks, et al
2012; 10 (3): 320-338
 - **Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer** *JOURNAL OF CLINICAL INVESTIGATION*
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W., Clarke, M. F., Carlson, R. W., Stockdale, F. E., Mollick, J. A., Chen, et al
2012; 122 (3): 1066-1075
 - **Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial** *LANCET ONCOLOGY*
Lee, N. Y., Zhang, Q., Pfister, D. G., Kim, J., Garden, A. S., Mechalakos, J., Hu, K., Le, Q. T., Colevas, A. D., Glisson, B. S., Chan, A. T., Ang, K. K.
2012; 13 (2): 172-180
 - **The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck.** *Chemotherapy research and practice*
Russell, J. S., Colevas, A. D.
2012; 2012: 761518-?

- **Evaluation of patients with disseminated or locoregionally advanced thyroid cancer: a primer for medical oncologists.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Colevas, A. D., Shah, M. H.
2012; 384–88
- **Transsphenoidal Resection of Sellar Tumors Using High-Field Intraoperative Magnetic Resonance Imaging** *SKULL BASE-AN INTERDISCIPLINARY APPROACH*
Szerlip, N. J., Zhang, Y., Placantonakis, D. G., Goldman, M., Colevas, K. B., Rubin, D. G., Kobylarz, E. J., Karimi, S., Girotra, M., Tabar, V.
2011; 21 (4): 223-232
- **Head and Neck Cancers** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Ang, K., Brizel, D. M., Burtneess, B. A., Cmelak, A. J., Colevas, D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, R. I., Haughey, B. H., Hicks, et al
2011; 9 (6): 596-649
- **A POOLED ANALYSIS OF ADVANCED NONSQUAMOUS NSCLC PATIENTS WITH STABLE TREATED BRAIN METASTASES IN TWO PHASE II TRIALS RECEIVING BEVACIZUMAB AND PEMETREXED AS SECOND-LINE THERAPY**
Gubens, M., Akerley, W., Lynch, T., Langer, C. J., Socinski, M. A., Colevas, A., Clement-Duchene, C., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2011: S1224–S1225
- **Controversies in the Locoregional Management of Head and Neck Cancer** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Brizel, D. M., Lydiatt, W., Colevas, A. D.
2011; 9 (6): 653-662
- **Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.**
Sikic, B. I., Eckhardt, S. G., Gallant, G., Burris, H. A., Camidge, D. R., Colevas, A. D., Jones, S. F., Messersmith, W. A., Wakelee, H. A., Li, H., Kaminker, P. G., Morris, S., Infante, et al
AMER SOC CLINICAL ONCOLOGY.2011
- **Chemoradiation for nasopharyngeal carcinoma (NPC) with pilot hypoxia imaging with F18 misonidazole PET scanning.**
Colevas, A. D., Quon, A., McMillan, A., Le, Q.
AMER SOC CLINICAL ONCOLOGY.2011
- **A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors**
Rosen, L., LoRusso, P., Ma, W., Goldman, J., Weise, A., Colevas, A., Adjei, A., Yazji, S., Shen, A., Johnston, S., Gates, M. R., Jones, C., Musib, et al
AMER ASSOC CANCER RESEARCH.2011
- **INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
Daly, M. E., Le, Q., Jain, A. K., Maxim, P. G., Hsu, A., Loo, B. W., Kaplan, M. J., Fischbein, N. J., Colevas, A. D., Pinto, H., Chang, D. T.
2011; 33 (1): 103-111
- **A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., Kumar, A., Zhao, G., Padda, S., Zhou, L., San Pedro-Salcedo, M., Colevas, A. D., Wakelee, H. A.
2010; 5 (11): 1821-1825
- **HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETNAMESE AMERICAN MEN IN CALIFORNIA** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
Filion, E. J., McClure, L. A., Huang, D., Seng, K., Kaplan, M. J., Colevas, A. D., Gomez, S. L., Chang, E. T., Le, Q.
2010; 32 (10): 1336-1344
- **MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN LOCALLY ADVANCED HEAD-AND-NECK CANCER** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Van Waes, C., Allen, C. T., Citrin, D., Gius, D., Colevas, A. D., Harold, N. A., Rudy, S., Nottingham, L., Muir, C., Chen, Z., Singh, A. K., Dancy, J., Morris, et al
2010; 77 (2): 447-454
- **Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.**

Eckhardt, S. G., Gallant, G., Sikic, B. I., Camidge, D. R., Burris, H. A., Wakelee, H. A., Messersmith, W. A., Jones, S. F., Colevas, A. D., Infante, J. R.
AMER SOC CLINICAL ONCOLOGY.2010

- **A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer**
He, A. R., Kunz, P. L., Pishvaian, M. J., Colevas, A. D., Hwang, J. J., Clemens, P. L., Messina, M., Kaleta, R., Abrahao, F., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2010
- **Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors**
Fan, A. C., Dermody, J., Kong, C., Zhang, N., Colevas, A. D., Felsher, D. W.
AMER SOC CLINICAL ONCOLOGY.2010
- **Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP)**
Cao, H., Kwok, S., Shi, X., Bala, R., Pinsky, B., Colevas, A. D., Pourmand, N., Koong, A., Kong, C., Le, Q.
AMER SOC CLINICAL ONCOLOGY.2010
- **A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity**
Colevas, A. D., Clarke, C. A., Lichtensztajn, D., Chang, E. T.
AMER SOC CLINICAL ONCOLOGY.2010
- **Toxicity Monitoring: Why, What, When?** *ONCOLOGY CLINICAL TRIALS*
Colevas, A., Kelly, W. K., Halabi, S.
2010: 151–61
- **Intensity Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure**
Wiegner, E. A., Daly, M. E., Chapman, C. H., Yu, Y., Colevas, A. D., Kaplan, M. J., Fischbein, N., Le, Q. T., Chang, D. T.
ELSEVIER SCIENCE INC.2010: S463
- **Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors**
Chang, C. N., Zhou, L. Y., MacFarlane, G., Tran, P., Rao, A., Chapman, C., Le, Q., Wakelee, H., Colevas, A. D., Whyte, R., Hristov, D., Dieterich, S., Maxim, et al
LIPPINCOTT WILLIAMS & WILKINS.2009: S938–S939
- **Quantification of pre-treatment metabolic tumor growth rate in lung cancer**
Eastham, D., Chapman, C. H., Rao, A. K., Balasubramanian, N., Quon, A., Vasanawala, M. S., Wakelee, H., Le, Q., Colevas, D. A., Maxim, P. A., Graves, E., Loo, B. W.
LIPPINCOTT WILLIAMS & WILKINS.2009: S733–S733
- **LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD-AND-NECK CANCER** *49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*
Citrin, D., Mansueti, J., Likhacheva, A., Sciuto, L., Albert, P. S., Rudy, S. F., Cooley-Zgela, T., Cotrim, A., Solomon, B., Colevas, A. D., Russo, A., Morris, J. C., Herscher, et al
ELSEVIER SCIENCE INC.2009: 1040–46
- **Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Eastham, D. V., Chapman, C. H., Rao, A. K., Narasimhan, B., Quon, A., Vasanawala, M. S., Wakelee, H., Le, Q., Colevas, A. D., Loo, B. W.
ELSEVIER SCIENCE INC.2009: S446–S446
- **Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms**
Grant, S., Sullivan, D., Roodman, D., Stuart, R. K., Perkins, E., Kolla, S., Rarnakrishnan, V., Wright, J., Colevas, A., Tombes, M. B., Roberts, J. D.
AMER SOC HEMATOLOGY.2008: 558
- **A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma** *BRITISH JOURNAL OF HAEMATOLOGY*
O'Connor, O. A., Portlock, C., Moskowitz, C., Straus, D., Hamlin, P., Stubblefield, M., Dumetrescu, O., Colevas, A. D., Grant, B., Zelenetz, A.
2008; 143 (2): 201-209
- **Head and neck cancers.** *Journal of the National Comprehensive Cancer Network*
Forastiere, A. A., Ang, K., Brizel, D., Brockstein, B. E., Burtness, B. A., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Goepfert, H., Hicks, W. L., Kies, M. S., Lydiatt, et al
2008; 6 (7): 646-695

- **Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck** *31st Congress of the European-Society-for-Medical-Oncology*
Tang, P. A., Siu, L. L., Chen, E. X., Hotte, S. J., Chia, S., Schwarz, J. K., Pond, G. R., Johnson, C., Colevas, A. D., Synold, T. W., Vasisst, L. S., Winquist, E.
SPRINGER.2008: 257–64
- **Intensity modulated radiotherapy for squamous cell carcinoma of the hypopharynx and larynx: Clinical outcomes and patterns of failure**
Daly, M. E., Le, Q. T., Loo, B. W., Maxim, P. G., Pinto, H. A., Colevas, A. D., Fee, W. E., Kaplan, M. J., Chang, D. T.
ELSEVIER SCIENCE INC.2008: S405–S406
- **High incidence of larynx cancers in Vietnamese population in the bay area**
Huang, D. D., Filion, E. J., Chang, E., Colevas, A. D., Kaplan, M. J., Le, Q.
ELSEVIER SCIENCE INC.2008: S484
- **A phase 2 trial of flavopiridol and cisplatin in platinum-resistant ovarian cancer**
Peethambaram, P. P., Burton, J. K., Oberg, A. L., Gomez-Dahl, L. C., Isham, C. R., Tibodeau, J. D., Chomjak, T. L., Colevas, A., Wright, J. J., Erlichman, C., Bible, K. C.
AMER ASSOC CANCER RESEARCH.2007: 3380S–3381S
- **Patient-reported outcomes and the evolution of adverse event reporting in oncology** *JOURNAL OF CLINICAL ONCOLOGY*
Trotti, A., Colevas, A. D., Setser, A., Basch, E.
2007; 25 (32): 5121-5127
- **Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer** *NEW ENGLAND JOURNAL OF MEDICINE*
Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., Murphy, B. A., Raez, L. E., Cohen, et al
2007; 357 (17): 1705-1715
- **A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors** *INVESTIGATIONAL NEW DRUGS*
Hensley, M. L., Dizon, D., Derosa, F., Venkatraman, E., Sabbatini, P., Chi, D. S., Dupont, J., Colevas, A. D., Spriggs, D., Aghajanian, C.
2007; 25 (4): 335-341
- **Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia** *CLINICAL CANCER RESEARCH*
Karp, J. E., Smith, B. D., Levis, M. J., Gore, S. D., Greer, J., Hattenburg, C., Briel, J., Jones, R. J., Wright, J. J., Colevas, A. D.
2007; 13 (15): 4467-4473
- **Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models** *CLINICAL CANCER RESEARCH*
Albert, J. M., Cao, C., Kim, K. W., Willey, C. D., Geng, L., Xiao, D., Wang, H., Sandler, A., Johnson, D. H., Colevas, A. D., Low, J., Rothenberg, M. L., Lu, et al
2007; 13 (10): 3033-3042
- **Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma** *9th Annual Meeting of the Society-for-Neuro-Oncology*
Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Zhang, Y., Carson, K., Wittemer, S. M., Colevas, A. D., Grossman, S. A.
AMER SOC CLINICAL ONCOLOGY.2007: 1651–57
- **A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma** *CANCER BIOLOGY & THERAPY*
Posadas, E. M., Undevia, S., Manchen, E., Wade, J. L., Colevas, A. D., Karrison, T., Vokes, E. E., Stadler, W. M.
2007; 6 (4): 490-493
- **Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia** *BLOOD*
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L. J., Johnson, et al
2007; 109 (2): 399-404
- **Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours** *EUROPEAN JOURNAL OF CANCER*
Messersmith, W. A., Rudek, M. A., Baker, S. D., Zhao, M., Collins, C., Colevas, A. D., Donehower, R. C., Carducci, M. A., Wolff, A. C.
2007; 43 (1): 78-86
- **Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone** *ANNALS OF ONCOLOGY*

- Mani, S., McDavid, H. M., Grossman, A., Muggia, F., Goel, S., Griffin, T., Colevas, D., Horwitz, S. B., Egorin, M. J.
2007; 18 (1): 190-195
- **Long term followup of a phase I study of concurrent paclitaxel and radiation for locally advanced squamous cell carcinoma of the head and neck** *49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*
Mansueti, J., Likhacheva, A., Albert, P., Scuito, L., Harold, N., Rudy, S., Colevas, D., Morris, J. C., Van Waes, C., Citrin, D.
ELSEVIER SCIENCE INC.2007: S444-S444
 - **Adverse event reporting in publications compared with sponsor database for cancer clinical trials** *JOURNAL OF CLINICAL ONCOLOGY*
Scharf, O., Colevas, A. D.
2006; 24 (24): 3933-3938
 - **Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck** *JOURNAL OF CLINICAL ONCOLOGY*
Colevas, A. D.
2006; 24 (17): 2644-2652
 - **Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design** *CLINICAL GENITOURINARY CANCER*
Beekman, K. W., Colevas, A. D., Cooney, K., DiPaola, R., Dunn, R. L., Gross, M., Keller, E. T., Pienta, K. J., Ryan, C. J., Smith, D., Hussain, M.
2006; 4 (4): 299-302
 - **In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent** *CLINICAL CANCER RESEARCH*
Rudek, M. A., Zhao, M., Smith, N. F., Robey, R. W., He, P., Hallur, G., Khan, S., Hidalgo, M., Jimeno, A., Colevas, A. D., Messersmith, W. A., Wolff, A. C., Baker, et al
2005; 11 (23): 8503-8511
 - **Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias** *CLINICAL CANCER RESEARCH*
Karp, J. E., Passaniti, A., Gojo, I., Kaufmann, S., Bible, K., Garimella, T. S., Greer, J., Briel, J., Smith, B. D., Gore, S. D., Tidwell, M. L., Ross, D. D., Wright, et al
2005; 11 (23): 8403-8412
 - **Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Hussain, M., Tangen, C. M., Lara, P. N., Vaishampayan, U. N., Petrylak, D. P., Colevas, A. D., Sakr, W. A., Crawford, E. D.
AMER SOC CLINICAL ONCOLOGY.2005: 8724-29
 - **Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma** *37th Annual Meeting of the American-Society-of-Clinical-Oncology*
Amrein, P. C., Clark, J. R., Supko, J. G., Fabian, R. L., Wang, C. C., Colevas, A. D., Posner, M. R., Deschler, D. G., Rocco, J. W., Finkelstein, D. M., McIntyre, J. F.
JOHN WILEY & SONS INC.2005: 1418-27
 - **Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 213 design** *CLINICAL CANCER RESEARCH*
Gadgeel, S. M., Wozniak, A., Boinpally, R. R., Wiegand, R., Heilbrun, L. K., Jain, V., Parchment, R., Colevas, D., Cohen, M. B., LoRusso, P. M.
2005; 11 (17): 6233-6239
 - **Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Galsky, M. D., Small, E. J., Oh, W. K., Chen, I., Smith, D. C., Colevas, A. D., Martone, L., Curley, T., Delacruz, A., Scher, H. I., Kelly, W. K.
AMER SOC CLINICAL ONCOLOGY.2005: 1439-46
 - **Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent** *ONCOLOGY-NEW YORK*
Colevas, A. D., Scharf, O., Schoenfeldt, M.
2004; 18 (14): 1778-?
 - **Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma** *INVESTIGATIONAL NEW DRUGS*
Burdette-Radoux, S., Tozer, R. G., Lohmann, R. C., Quirt, I., Ernst, D. S., Walsh, W., Wainman, N., Colevas, A. D., Eisenhauer, E. A.
2004; 22 (3): 315-322
 - **The clinical development of new mitotic inhibitors that stabilize the microtubule** *ANTI-CANCER DRUGS*
Mani, S., Macapinlac, M., Goel, S., Verdier-Pinard, D., Fojo, T., Rothenberg, M., Colevas, D.

2004; 15 (6): 553-558

- **HER2 expression in salivary gland carcinomas: Dependence on histological subtype** *CLINICAL CANCER RESEARCH*
Glisson, B., Colevas, A. D., Haddad, R., Krane, J., El-Naggar, A., Kies, M., Costello, R., Summey, C., Arquette, M., Langer, C., Amrein, P. C., Posner, M.
2004; 10 (3): 944-946
- **Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study** *ORAL ONCOLOGY*
Haddad, R., Colevas, A. D., Krane, J. F., Cooper, D., Glisson, B., Amrein, P. C., Weeks, L., Costello, R., Posner, M.
2003; 39 (7): 724-727
- **CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment** *SEMINARS IN RADIATION ONCOLOGY*
Trotti, A., Colevas, A. D., SETSER, A., Rusch, V., Jaques, D., Budach, V., Langer, C., Murphy, B., Cumberlin, R., Coleman, C. N., Rubin, P.
2003; 13 (3): 176-181
- **Development of investigational radiation modifiers** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Colevas, A. D., Brown, J. M., Hahn, S., Mitchell, J., Camphausen, K., Coleman, C. N.
2003; 95 (9): 646-651
- **Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck - The Dana Farber Cancer Institute experience** *CANCER*
Haddad, R., Colevas, A. D., Tishler, R., Busse, P., Goguen, L., Sullivan, C., Norris, C. M., Lake-Willcutt, B., Case, M. A., Costello, R., Posner, M.
2003; 97 (2): 412-418
- **Organ preservation-induction chemotherapy.** *Cancer treatment and research*
Colevas, A. D.
2003; 114: 213-234
- **Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial** *CLINICAL CANCER RESEARCH*
Karp, J. E., Ross, D. D., Yang, W. D., Tidwell, M. L., Wei, Y. T., Greer, J., Mann, D. L., Nakanishi, T., Wright, J. J., Colevas, A. D.
2003; 9 (1): 307-315
- **A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck** *37th Annual Meeting of the American-Society-of-Clinical-Oncology*
Tishler, R. B., Norris, C. M., Colevas, A. D., Lamb, C. C., Karp, D., Busse, P. M., Nixon, A., Frankenthaler, R., Lake-Willcutt, B., Costello, R., Case, M., Posner, M. R.
JOHN WILEY & SONS INC.2002: 1472-81
- **Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN)** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Colevas, A. D., Norris, C. M., Tishler, R. B., Lamb, C. C., Fried, M. P., Goguen, L. A., Gopal, H. V., Costello, R., Read, R., Adak, S., Posner, M. R.
2002; 25 (2): 153-159
- **Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Colevas, A. D., Read, R., Thornhill, J., Adak, S., Tishler, R., Busse, P., Li, Y., Posner, M.
2001; 51 (3): 599-604
- **Clinical trials referral resource: Current clinical trials of epothilone B analog (BMS-247550)** *ONCOLOGY-NEW YORK*
Colevas, A. D., West, P. J., Cheson, B. D.
2001; 15 (9): 1168-?
- **A Phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Colevas, A. D., Amrein, P. C., Gomolin, H., Barton, J. J., Read, R. R., Adak, S., Benner, S., Costello, R., Posner, M. R.
JOHN WILEY & SONS INC.2001: 326-31
- **Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck** *JOURNAL OF CLINICAL ONCOLOGY*
Posner, M. R., Glisson, B., Frenette, G., al-Sarraf, M., Colevas, A. D., Norris, C. M., Seroskie, J. D., Shin, D. M., Olivares, R., Garay, C. A.
2001; 19 (4): 1096-1104

- **NCCN Practice Guidelines for head and neck cancers** *ONCOLOGY-NEW YORK*
Forastiere, A. A., Pfister, D. G., Ang, K., Brockstein, B., Colevas, A. D., Ellenhorn, J., Goepfert, H., Hicks, W. L., Hong, W. K., Kies, M. S., Lydiatt, W., McCaffrey, T., Mittal, et al
2000; 14 (11A): 163-194
- **The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck** *SEMINARS IN ONCOLOGY*
Posner, M. R., Colevas, A. D., Tishler, R. B.
2000; 27 (4): 13-24
- **A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck** *ANNALS OF ONCOLOGY*
Colevas, A. D., Adak, S., Amrein, P. C., Barton, J. J., Costello, R., Posner, M. R.
2000; 11 (5): 535-539
- **Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck** *JOURNAL OF CLINICAL ONCOLOGY*
Colevas, A. D., Norris, C. M., Tishler, R. B., Fried, M. P., Gomolin, H. I., Amrein, P., Nixon, A., Lamb, C., Costello, R., Barton, J., Read, R., Adak, S., Posner, et al
1999; 17 (11): 3503-3511
- **Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck 20: 758-762, 1998)** *Head & neck*
Colevas, A. D.
1999; 21 (6): 582-?
- **An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies** *33rd Annual Meeting of the American-Society-of-Clinical-Oncology*
Tishler, R. B., Busse, P. M., Norris, C. M., Rossi, R., Poulin, M., Thornhill, L., Costello, R., Peters, E. S., Colevas, A. D., Posner, M. R.
ELSEVIER SCIENCE INC.1999: 1001-8
- **Intramucosal spread of malignant melanoma of the oral cavity** *OTOLARYNGOLOGY-HEAD AND NECK SURGERY*
Bhattacharyya, N., Norris, C. M., Colevas, A. D., Chasse, T. A.
1998; 119 (6): 711-711
- **Docetaxel in head and neck cancer - A review** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Colevas, A. D., Posner, M. R.
1998; 21 (5): 482-486
- **Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial** *JOURNAL OF CLINICAL ONCOLOGY*
Colevas, A. D., Busse, P. M., Norris, C. M., Fried, M., Tishler, R. B., Poulin, M., Fabian, R. L., Fitzgerald, T. J., Dreyfuss, A., Peters, E. S., Adak, S., Costello, R., Barton, et al
1998; 16 (4): 1331-1339
- **The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck.** *oncologist*
Posner, Johnston, Tishler, ANDERSEN, Fiorentino, Busse, Cavacini, Colevas, Clark, NORRIS
1998; 3 (6): 424-431
- **Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT.** *Oncology (Williston Park, N.Y.)*
Colevas, A. D.
1997; 11 (9): 86-89